Arovella Therapeutics (Australia) Today
| ALA Stock | 0.20 0.01 5.26% |
Performance4 of 100
| Odds Of DistressLess than 19
|
Arovella Therapeutics is selling for under 0.2 as of the 25th of January 2025; that is 5.26 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.2. Arovella Therapeutics has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 26th of December 2024 and ending today, the 25th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Arovella Therapeutics is entity of Australia. It is traded as Stock on AU exchange. The company has 1.06 B outstanding shares. More on Arovella Therapeutics
Moving against Arovella Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Arovella Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arovella Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arovella Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Arovella Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Arovella Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsArovella Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arovella Therapeutics' financial leverage. It provides some insight into what part of Arovella Therapeutics' total assets is financed by creditors.
| |||||
Arovella Therapeutics (ALA) is traded on Australian Securities Exchange in Australia and employs 7 people. Arovella Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 212.14 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arovella Therapeutics's market, we take the total number of its shares issued and multiply it by Arovella Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arovella Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 1.06 B outstanding shares.
Arovella Therapeutics has accumulated about 5.18 M in cash with (6.91 M) of positive cash flow from operations.
Check Arovella Therapeutics Probability Of Bankruptcy
Ownership AllocationArovella Therapeutics holds a total of 1.06 Billion outstanding shares. Arovella Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arovella Ownership Details
Arovella Therapeutics Risk Profiles
Although Arovella Therapeutics' alpha and beta are two of the key measurements used to evaluate Arovella Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.11 | |||
| Semi Deviation | 3.38 | |||
| Standard Deviation | 4.28 | |||
| Variance | 18.28 |
Arovella Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Arovella Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Arovella Therapeutics Corporate Management
Elected by the shareholders, the Arovella Therapeutics' board of directors comprises two types of representatives: Arovella Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arovella. The board's role is to monitor Arovella Therapeutics' management team and ensure that shareholders' interests are well served. Arovella Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arovella Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tony Macintyre | GM CTO | Profile | |
| Stephen Carter | Consultant | Profile | |
| Richard Franklin | Project Board | Profile | |
| BSc BSc | Chief Officer | Profile | |
| Michelle Long | Administration Manager | Profile | |
| Bus CA | Company CFO | Profile | |
| Michael Baker | MD CEO | Profile |
Additional Tools for Arovella Stock Analysis
When running Arovella Therapeutics' price analysis, check to measure Arovella Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arovella Therapeutics is operating at the current time. Most of Arovella Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arovella Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arovella Therapeutics' price. Additionally, you may evaluate how the addition of Arovella Therapeutics to your portfolios can decrease your overall portfolio volatility.